Statistics Workbook for Evidence-Based Health Care

Statistics Workbook for Evidence-Based Health Care

Volumn , Issue , 2009, Pages 1-182

  Peat, Jennifer ^a   Barton, Belinda ^b   Elliott, Elizabeth ^b,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Centre for Evidence Based Paediatrics Gastroenterology and Nutrition   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887225267     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300499     Document Type: Book

References (334)

1. O'Rourke MF.Editorial. William Osler: a model for the 21st century? Med J Aust.1999; 171:577-579.
2. Moyer VA, Elliott EJ, et al. (eds.) Evidence based pediatrics and childhealth. BMJ Books 2004 (2nd Edition). London: BMJ Books.
3. Bland JM, Peacock J. Statistical questions in evidence-basedmedicine. New York: Oxford University Press, 2000.
4. Guyatt GH, Rennie D. Users' guide to the medical literature. Essentialsof evidence-based practice. JAMA and Archives Journals, Chicago:AMA Press, 2002.
5. Sackett DL, Haynes RB, Guyatt GJ, Tugwell P. Clinical epidemiology.A basic science for clinical medicine. Boston: Little, Brown andCompany, 1991.
6. Peat JK, Mellis CM, Williams K, Xuan W. Study design. Health scienceresearch. A handbook of quantitative methods.Crow's Nest,Australia: Allen and Unwin, 2001.
7. Ott A, Stolk RP, Van Harskamp F, Pols HA, Hofman A, Breteler MM.Diabetes mellitus and the risk of dementia: the Rotterdam study.Neurology 1999;53:1937-42.
8. Healy MJR. Is statistics a science? J R Statist Soc A 1978; 141:385-393.
9. Altman DG.Statistics in medical journals. Stat Med.1982; 1:59-71.
10. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR.The importanceof beta, the type II error and sample size in the design and interpretationof the randomized control trial. N Engl J Med.1978; 299:690-694.
11. Garraway WM, Akhtar AJ, Prescott RJ, Hockey L. Management ofacute stroke in the elderly: preliminary results of a controlled trial.Br Med J 1980; 280:1040-1043.
12. Gardner MJ, Altman DG.Confidence intervals rather than P values:estimation rather than hypothesis testing. Br Med J.1986; 292:746-750.
13. Ott A, Stolk RP, Van Harskamp F, Pols HA, Hofman A, Breteler MM.Diabetes mellitus and the risk of dementia: the Rotterdam study.Neurology 1999; 53:1937-42.
14. Leibson CL, Rocca, WA, Hanson VA, Cha R, Kokmen E,O'Brien PC, et al.Risk of dementia among persons with diabetesmellitus: a population-based cohort study. Am J Epidemiol.1997; 145:301-8.
15. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW,Masaki KH, et al.Longitudinal association of vascular andAlzheimer's dementias, diabetes, and glucose tolerance. Neurology.1999; 52:971-5.
16. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeaux R.Diabetes mellitusand risk of Alzheimer's disease and dementia with stroke in amultiethnic cohort. Am J Epidemiol.2001; 154:635-41.
17. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitusand the risk of dementia, Alzheimer's disease and vascularcognitive impairment in the Canadian study of health and aging.Dement Geriatr Cogn Disord 2002; 14:77-83.
18. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL.Mildcognitive impairments predict dementia in nondemented elderlypatients with memory loss. Arch Neurol.2001; 58:411-6.
19. Brookmeyer R, Gray S, Kawas C.Projections of Alzheimer'sdisease in the United States and the public health impact of delayingdisease onset. Am J Pub Health.1998; 88:1337-42.
20. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, NarayanKM, et al.Is diabetes associated with cognitive impairment andcognitive decline among older women? Study of OsteoporoticFractures Research Group. Arch Intern Med.2000; 160:174-80.
21. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M,et al.Cardiovascular risk factors and cognitive decline in middleagedadults. Neurology.2001; 56:42-8.
22. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D.Glucoseintolerance, hyperinsulinaemia and cognitive function in a generalpopulation of elderly men. Diabetologia.1995; 38:1096-102.
23. Scott RD, Kritz-Silverstein D, Barrett-Connor E, WiederholtWC.The association of non-insulin-dependent diabetes mellitusand cognitive function in an older cohort. J Am Geriatr Soc.1998; 46:1217-22.
24. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A.Changes incognitive abilities over a 4-year period are unfavorably affected inelderly diabetic subjects: results of the epidemiology of vascularaging study. Diabetes Care.2001; 24:366-70.
25. Stolk RP, Breteler MM, Ott A, Pols HA, Lamberts, SW, Grobbee DE,et al.Insulin and cognitive function in an elderly population. TheRotterdam study. Diabetes Care.1997; 20:792-5.
26. Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW,Silbershatz H, et al.NIDDM and blood pressure as risk factorsfor poor cognitive performance. The Framingham study. DiabetesCare.1997; 20:1388-95.
27. Rodriguez-Saldana J, Morley JE, Reynoso MT, Medina CA, SalazarP, Cruz E, et al.Diabetes mellitus in a subgroup of older Mexicans:prevalence, association with cardiovascular risk factors, functionaland cognitive impairment, and mortality. J Am Geriatr Soc.2002; 50:111-6.
28. Nguyen HT, Black SA, Ray LA, Espino DV, Markides KS. Predictorsof decline in MMSE scores among older Mexican Americans. JGerontol A Biol Sci Med Sci 2002;57:M181-5.
29. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH.Impact of diabetes on cognitive function among older Latinos: apopulation-based cohort study. J Clin Epidemiol 2003; 56:686-93.
30. Vanhanen M, Kuusisto J, Koivisto K, Mykkanen L, Helkala EL,Hanninen T, et al.Type-2 diabetes and cognitive function in a nondementedpopulation. Acta Neurol Scand.1999; 100:97-101.
31. Lindeman RD, Romero LJ, LaRue A, Yau CL, Schade DS,Koehler KM, et al. A biethnic community survey of cognition inparticipants with type 2 diabetes, impaired glucose tolerance, andnormal glucose tolerance: the New Mexico elder health survey.Diabetes Care 2001; 24:1567-72.
32. Coker LH, Shumaker SA.Type 2 diabetes mellitus and cognition:an understudied issue in women's health. J Psychosom Research.2003; 54:129-39.
33. Kang JH, Grodstein F.Regular use of nonsteroidal anti-inflammatorydrugs and cognitive function in aging women. Neurology.2003; 60:1591-7.
34. Brandt J, Spencer M, Folstein M.The telephone interview forcognitive status. Neuropsychiatry Neuropsychol Behav Neurol.1988; 1:111-7.
35. National Diabetes Data Group.Classification and diagnosis of diabetesmellitus and other categories of glucose intolerance. Diabetes.1979; 28:1039-57.
36. Expert Committee on the Diagnosis and Classification of DiabetesMellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2000;SUPPL 1:S4-19.
37. Manson JE, Rimm EB, Stampfer MJ, Colditz GA,Willett WC, Krolewski AS, et al.Physical activity and incidenceof non-insulin-dependent diabetes mellitus in women. Lancet.1991; 338:774-8.
38. Vickers A, Altman D.Analysing controlled trials 26 ials with baseline andfollow-up measurements. BMJ.2001; 323:1123-4.
39. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA,Frosch MP, et al.Insulin-degrading enzyme regulates the levelsof insulin, amyloid beta-protein, and the beta-amyloid precursorprotein intracellular domain in vivo. Proc Natl Acad Sci USA.2003; 100:4162-7.
40. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, ChapmanD, et al.Insulin increases CSF Abeta42 levels in normal olderadults. Neurology.2003; 60:1899-903.
41. Testa MA, Simonson DC.Health economic benefits and quality oflife during improved glycemic control in patients with type 2 diabetesmellitus: a randomized, controlled, double-blind trial. JAMA.1998; 280:1490-6.
42. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH.Impact of antidiabetic medications on physical and cognitivefunctioning of older Mexican Americans with diabetes mellitus: apopulation-based cohort study. Ann Epidemiol 2003; 13:369-76.
43. Evans SJ.Good surveys guide. BMJ.1991; 302:302-303.
44. Berry G.Statistical significance and confidence intervals. Med J Aust.1986; 144:618-619.
45. Altman D. Confidence intervals in research evaluation. ACP J Club 1992;116:A28-A29.
46. Lang TA, Secic M. Rules for presenting numbers in text. In: How toreport statistics in medicine. Philadelphia, Pennsylvania: AmericanCollege of Physicians, 1997; pp 339-341.
47. Gallagher SM.Outcomes in clinical practice: pressuree ulcerprevalence and incidence studies. Ostomy Wound Manage.1997; 43:28-35.
48. Frantz RA. Measuring prevalence and incidence of pressure ulcers.Adv Wound Care 1997;10(1):21-4.
49. Peat JK, van den Berg RH, Green WF, Mellis CM, Leeder SR,Woolcock AJ. Changing prevalence of asthma in Australian children.BMJ 1994; 308:1591-6.
50. Peat JK, Li J. Reversing the trend: Reducing the prevalence of asthma.J Allergy Clin lmmunol 1999; 103:1-10.
51. Britton WJ, Woolcock AJ, Peat JK, Sedgwick CJ, Lloyd DM,Leeder SR.Prevalence of bronchial hyperresponsiveness inchildren: the relationship between asthma: the relationship betweenasthma and skin reactivity to allergens in two communities. Int JEpidemiol.1986; 15:202-9.
52. Drane JW Imputing nonresponses to mail-back questionnaires.Am J Epidemiol 1991; 134:908-12.
53. de Marco R, Verlato G, Zanolin E, Bugiani M, Drane JW.Nonresponse bias in EC respiratory health survey in Italy. EurRespir J 1994; 7:2139-45.
54. Health Protection Agency, Scottish Centre for Infection and Environmental Health, National Public Health Service for Wales,Communicable Disease Surveillance Centre Northern Ireland,Centre for Research on Drugs and Health Behaviour, UnlinkedAnonymous Surveys Steering Group. Shooting up: infections amonginjecting drug users in the United Kingdom 2002. London: HPA,2003.
55. Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, et al.Evaluation of a modified commercial assay in detecting antibody tohepatitis C virus in oral fluids and dried blood spots. J Med Virol2003; 71:49-55.
56. Connell JA, Parry JV, Mortimer PP, Duncan J.Novel assay for thedetection of immunoglobulin G antihuman immunodeficiencyvirus in untreated saliva and urine. J Med Virol.1993; 41:159-64.
57. Murphy G, Charlett A, Jordan LF, Osner N, Gill ON, Parry JV.HIV incidence appears constant in men who have sex with mendespite widespread use of effective antiretroviral therapy. AIDS2004; 18:265-72.
58. Hickman M, Higgins V, Hope VD, Bellis MA, Tilling K, Walker A,et al. Injecting drug use in Brighton, Liverpool, and London: bestestimates of prevalence and coverage of public health indicators.J Epidemiol Community Health 2004; 58:766-71.
59. Bland JM. The chi-square test for association. In: An introductionto medical statistics. Oxford: Oxford University Press, 1996;pp 225-235.
60. Altman DG. Ordered categories. In: Practical statistics for medicalresearch. London: Chapman & Hall, 1996; pp 261-265.
61. Bleck TP. Clostridium tetani (tetanus). In: Mandell GL, BennettJE, Dolin R, eds. Mandell, Douglas, and Bennett's principles andpractice of infectious diseases. Philadelphia: Churchill Livingstone,2000;2537-43.
62. Thwaites CL, Farrar JJ.Preventing and treating tetanus. The challengecontinues in the face of neglect and lack of research. BMJ.2003; 326:117-8.
63. Edmondson RS, Flowers MW.Intensive care in tetanus: management,complications and mortality in 100 cases. BMJ.1979; 1:1401-4.
64. Harding-Goldson HE, Hanna WJ.Tetanus: a recurring intensivecare problem. J Trop Med Hyg.1995; 98:179-84.
65. Sanders RKM, Martyn B, Joseph R, Peacock ML.Intrathecalantitetanus serum (horse) in the treatment of tetanus. Lancet.1977; 1:974-7.
66. Vakil BJ, Armitage P, Clifford RE, Laurence DR.Therapeutictrial of intracisternal human tetanus immunoglobulin in clinicaltetanus. Trans R Soc Trop Med Hyg.1979; 73:579-83.
67. pta PS, Goyal S, Kapoor R, Batra VK, Jain BK.Intrathecal 7 athecal humantetanus immunoglobulin in early tetanus. Lancet.1980; 2:439-40.
68. Keswani NK, Singh AK, Upadhyana KD.Intrathecal tetanusanti-toxin in moderate and severe tetanus. J Indian Med Assoc.1980; 75:67-9.
69. Rossano C, Giugliano F. Prime esperienze e risultati terapeuticicon immunoglobuline umane antitetaniche per via subaracnoidea.Minerva Anestesiol 1970; 36:725-7.
70. Ildirim I.Intrathecal treatment of tetanus with antitetanus serumand prednisolone mixture. In: International Conference onTetanus, São Paulo. Pan American Health Organisation-Scientpublic.1972; 253:119-26.
71. Veronesi R, Bizzini B, Hutzler RU, Focaccia R, Mazza CC,Feldman C, et al.Eficácia do tratamiento do tétano com antitoxinatetânica por via raquideana e/ou venosa. Estudo de 101 casos, compesquisa sobre a permanência da gamaglobulina humana-F(ab)2-no1íqüor e no sangue. Revista brasileira Clínica e Terapêutica.1980; 9:301-19.
72. Sun KO, Chan YW Cheung RTF, So PC, Yu YL, Li PCK Managementof tetanus: a review of 18 cases. J R Soc Med 1994; 87:135-7.
73. Gallais, H. Intérêt de l'administration intrathécale de sérumantitétanique et de corticoïdes pour le treatment du tétanosdéclaré. La Nouvelle Presse médicale 1977;6:571.
74. List WF. The immediate treatment of tetanus with high doses ofhuman tetanus antitoxin. Nofallmedizin 1981;7:731-3.
75. Thomas PP, Crowell EB, Mathew M.Intrathecal anti-tetanus serum(ATS) and parenteral betamethasone in treatment of tetanus. TransR Soc Trop Med Hyg.1982; 76:620-3.
76. Abrutyn E, Berlin JA.Intrathecal therapy in tetanus, ameta-analysis. JAMA.1991; 266:2262-7.
77. Friedman LM, Furberg CD, Demets DL. Fundamentals of clinicaltrials, 3rd ed. St Louis, MI: Mosby, 1996.
78. Miranda Filho DB, Ximenes RAA, Bernardino SN, Escarião AG.Caracterização epidemiológica do tétano no estado de Pernambucono período de 1981 a 1995. Resumos do IX Congresso Brasileirode Infectologia; 1996; Aug 25-9; Recife. Sociedade Brasileira deInfectologia.
79. Miranda Filho D, Ximenes R, Barone A, Vaz V, Vieira. Classificaçãoclínica de pacientes com tétano para monitoramento da resposta amedidas terapêuticas. Braz J Infect Dis 2003;7(suppl 1):S18.
80. Armitage P, Clifford R.Prognosis in tetanus: use of data from therapeutictrial. J Infect Dis.1978; 138:1-8.
81. Miranda Filho DB, Ximenes RAA, Bernardino SN, EscariãoAG.Identification of risk factors for death from tetanus inPernambuco, Brazil. A case control study. Rev Inst Med Trop SaoPaulo.2000; 42:333-9.
82. Agarwal M, Thomas K, Peter JV, Jeyaseelan L, Cherian AM.A randomised double-blind sham controlled study of intrathecalhuman anti-tetanus immunoglobulin in the management oftetanus. Natl Med J India 1998; 11:209-12.
83. Barone AA, Raineri HC, Ferreira JM.Tétano: aspectos epidemiológicos,clínicos e ter-apêuticos. Análise de 461 casos. Rev HospClin Fac Med Sao Paulo.1976; 31:215-25.
84. Udwadia FE, Lall A, Udwadia ZF, Sekhar M, Vora A.Tetanus and itscomplications: intensive care and management experience in 150Indian patients. Epidemiol Infect 1987;99:675-84.
85. Katz KA.The (relative) risks of using odds ratio. Arch 1. Dermatol.2006; 142:761-764.
86. Bland JM, Altman DG. The odds ratio. BMJ 2000;320:1468.
87. Altman DG. The odds ratio. In: Practical statistics for medicalresearch. London: Chapman & Hall, 1996; pp 268-271.
88. Peat JK, Mellis CM, Williams K, Xuan W. Confounders. In: Healthscience research. A handbook of quantitative methods. Sydney: Allenand Unwin, 2001; pp 92-97.
89. Zhang J, Yu KF.What's the relative risk? A method of c orrectingthe odds ratio in cohort studies of common outcomes. JAMA.1998; 280:1690-1691.
90. Sackett D, Deeks J, Altman DG. Down with odds ratios! Evidence-Based Med 1996; 1:164-166.
91. Cook TD.Up with odds ratios! A case for odds ratios when outcomesare common. Acad Emerg Med.2002; 9:1430-1434.
92. Peat JK. Can asthma be prevented? Evidence from epidemiologicalstudies of children in Australia and New Zealand in the last decade.Clin Exp Allergy 1998; 28:261-265.
93. Wise J. Links to tobacco industry influences review co1 nclusions.BMJ 1998; 316: 1554. (23 May.)
94. Barnes DE, Dero LA. Why review articles on the health effects ofpassive smoking reach different conclusions. JAMA 1998; 279:1566-1570. [Abstract/Free Full Text.]
95. Sackett DL, Deeks JJ, Altman DG. Down with odds ratios! Evidence-Based Med 1996; 1:164-166.
96. Deeks JJ. When can odds ratios mislead? BMJ 1998; 317: 1155-1156.[Free Full Text]. (25 October.)
97. Sinclair JC, Bracken MB.Clinically useful measures of effectin binary analyses of randomized trials. J Clin Epidemiol 1994; 47:881-9.
98. Deeks J. Swots corner: what is an odds ratio? Bandolier 1996;3(3):6-7.
99. Altman DG. Practical statistics for medical research. London:Chapman and Hall, 1991.
100. Department of Health. Immunisation against infectious diseases.London: HMSO, 1996.
101. World Health Organisation. Immunisation in practice. Module 8.During a session: giving immunisations. Geneva: WHO, 1998. (www.who.int/vaccines-documents/DoxTrng/H4IIP.htm (accessed 3October 2000).)
102. Department of Health. Current vaccine issues: action update. London:DoH, 1999. (Professional letter PL/CMO/99/5.)
103. Diggle L. A randomised controlled trial of different needle lengths onthe incidence of local reactions when administering the combinedinjection of diphtheria/pertussis/tetanus (DPT) and Haemophilusinfluenzae type b (Hib) to infants at 4-months of age [dissertation].London: Royal College of Nursing Institute, 1999.
104. Mark A, Carlsson R, Granstrom M.Subcutaneous versus intramuscularinjection for booster DT vaccination of adolescents. Vaccine.1999; 17:2067-72.
105. Scheifele DW, Bjornson G, Boraston S.Local adverse effects ofmeningo-coccal vaccine. Can Med Assoc J 1994;150:14-5.
106. Lieu T, Black S, Ray G, Martin K, Shinefield H, Weniger B. Thehidden costs of infant vaccination. Vaccine.2000; 19:33-41.
107. Freedman B.Equipoise and the ethics of clinical research. 1. N Engl JMed.1987; 317:141-145.
108. Altman DG.Randomisation: essential for reducing bias. BMJ.1991; 302:1481-1482.
109. Forder PM, Gebski VJ, Keech AC.Allocation concealment and blinding:when ignorance is bliss. Med J Aust.2005; 182:87-89.
110. Solomon MJ, McLeod RS.Surgery and the randomisedcontrolled trial: past, present and future. Med J Aust.1998; 169:380-383.
111. Fontanarosa PB, Rennie D, DeAngelis CD.Postmarketingsurveillance-lack of vigilance, lack of trust. JAMA.2004; 292:2647-2650.
112. Moher D, Dulberg CS, Wells GA.Statistical power, sample size,and their reporting in randomised controlled trials. JAMA.1994; 272:122-124.
113. Freeman BD, Danner RL, Banks SM, Natanson C.Safeguardingpatients in clinical trials with high mortality rates. Am J Respir CritCare Med.2001; 164:190-192.
114. Hollis S, Campbell F.What is meant by intention to treat analyses?Survey of published randomised controlled trials. BMJ.1999; 319:670-674.
115. Heritier SR, Gebski VJ, Keech AC.Inclusion of patients in clinicaltrial analysis: the intention-to-treat principle. Med J Aust.2003; 179:438-440.
116. Pocock S, White I. Trials stopped early: too good to be true? Lancet1999; 353:943-944.
117. Wilhelmsen L.Role of the data and safety monitoring committee(DSMC). Stat Med.2002; 21:2823-2829.
118. Meinert CL. Clinical trials and treatment effects monitoring.Control Clin Trials 1998; 19:515-522.
119. Pocock SJ.When to stop a clinical trial. BMJ.1992; 305:235-240.
120. Greenhalgh T. How to read a paper: Papers that report drug trials.BMJ 1997; 315:480-483.
121. Pocock SJ. Clinical trials: a practical approach. Chichester:John Wiley, 1983.
122. Anonymous.Guidelines for writing papers. BMJ.1991; 302:40-2.
123. Altman DG. A fair trial? BMJ 1984; 289:336-7.
124. Smithells RW, Sheppard S, Schorah CJ, et al. Possible prevention ofneural-tube defects by periconceptional vitamin supplementation.Lancet 1980;i:339-40.
125. Evans SJW.Good surveys guide. BMJ.1991; 302:302-3.
126. Anonymous. Guidelines on the care of laboratory animals and theiruse for scientific purposes. IV. Planning and design of experiments.London: Laboratory Animals Science Association and UniversitiesFederation for Animal Welfare, 1990.
127. Altman DG, Doré CJ.Randomisation and baseline comparisons inclinical trials. Lancet.1990; 335:149-53.
128. Gotzsche PC.Methodology and overt and hidden bias in reports of196 double-blind trials of non-steroidal antiinflammatory drugs inrheumatoid arthritis. Controlled Clin Trials.1989; 10:31-56.
129. Moher D, Schulz KF, Altman DG, et al, for the CONSORT group.The revised CONSORT statement for reporting randomized trials:explanation and elaboration. Ann Intern Med 2001; 134:663-694.
130. Fisher L, Dixon D, Jerson J, et al. Intention to treat in clinical trials.In: Peace K, editor. Statistical issues in drug research and development.New York: Marcel Dekker, 1990.
131. Gillings D, Koch G. The application of the principle of intention-totreatto the analysis of clinical trials. Clinical Research Bulletin. Basle:Santoz Pharma, September, 1990.
132. Hollis S, Campbell F.What is meant by intention to treat analysis?Survey of published randomized controlled trials. BMJ.1999; 319:670-674.
133. Kirby A, Gebski VJ, Keech AC.Determining the sample size in aclinical trial. Med J Aust.2002; 177:256-257.
134. Sackett D, Gent M.Controversy in counting and attributing eventsin clinical trials. N Engl J Med.1979; 301:1410-1412.
135. Peto R, Pike MC, Armitage P, et al.Design and analysis ofrandomized clinical trials requiring prolonged observation ofeach patient. Br J Cancer.1976; 34:585-612.
136. Armitage P. Exclusions, losses to follow-up and withdrawals inclinical trials. In: Shapiro SH, Louis TA, editors. Clinical trials.New York: Marcel Dekker, 1983.
137. Gail MH. Eligibility, exclusions, losses to follow-up, removal ofrandomised patients and uncounted events in cancer clinical trials.Cancer Treat Rep 1985; 69:1107-1113.
138. Sandler R, Halabi S, Baron J, et al.A randomized trial of aspirin toprevent colorectal adenomas in patients with previous colorectalcancer. N Engl J Med.2003; 348:883-890.
139. Cameron ID, Cumming RG, Kurrle SE, et al. A randomised trial ofhip protector use by frail older women living in their own homes.Injury Prevention 2003; 9:138-141.
140. Cakir B, Gebski V, Keech AC.Flow of participants in randomisedstudies. Med J Aust.2003; 718:347-349.
141. Altman DG, Bland JM. Standard deviations and standard errors. BMJ 2005;331:903.
142. Altman DG, Bland JM. The normal distribution. BMJ 1995;310:298.
143. Bland JM, Altman DG. The use of transformation when comparingtwo means. BMJ 1996;312:1153.
144. Bland JM. Deviations from the assumptions of t methods. In: An introduction to medical statistics. Oxford: Oxford University Press, 1996; pp 165-166.
145. Bland JM, Altman DG. Matching. BMJ 1994;309:1128.
146. Cohen, J.A power primer. Psych Bull.1992; 112:155-159.
147. Driscoll P, Lecky F.An introduction to hypothesis testing. Parametriccomparison of two groups-1. Emerg Med J.2001; 18:124-30.
148. Driscoll P, Lecky F, Crosby M.An introduction to estimation-1.Starting from z. J Accid Emerg Med.2000; 17:409-15.
149. Driscoll P, Lecky F.An introduction to estimation-2. From z to t.Emerg Med J.2001; 18:65-70.
150. Driscoll P, Lecky F, Crosby M.An introduction to statisticalinference. J Accid Emerg Med.2000; 17:357-63.
151. Altman D. Normal plot. In: Practical statistics for medical research.London: Chapman and Hall, 1997:133-43.
152. Driscoll P, Lecky F, Crosby M.An introduction to everydaystatistics-1. J Accid Emerg Med.2000; 17:205-11.
153. Allison K, Gosling P, Jones S, et al.Randomised trial of hydroxyethylstarch versus gelatine for trauma resuscitation. J Trauma.1999; 47:1114-21.
154. Boyd R, Hanson J. Prospective single blinded randomised controlledtrial of two orally administered activated charcoal preparations.J Accid Emerg Med 1999; 16:24-5.
155. Steele M, Nelson M, Sessier D, et al.Forced air speeds rewarming inaccidental hypothermia. J Trauma.1996; 27:479-84.
156. Altman D. Theoretical distributions. In: Practical statistics formedical research. London: Chapman and Hall, 1991:48-73.
157. Bland M.An introduction to medical statistics. Oxford: OxfordUniversity Press, 1987.
158. Gaddis G, Gaddis M. Introduction to biostatistics: Part 4,statistical inference techniques in hypothesis testing. Ann EmergMed.1990; 19:820-5.
159. Gardner M, Altman D. Calculating confidence intervals for meansand their differences. In: Statistics with confidence. London: BMJPublications, 1989:20-7.
160. Glaser A. Hypothesis testing In: High yield biostatistics. Baltimore:Williams and Wilkins, 1995:31-46.
161. Koosis D. Difference between means. In: Statistics-a self teachingguide. 4th ed. New York: Wiley, 1997:127-52.
162. Swincow T. The t test. In: Statistics from square one. London: BMJPublications, 1983:33-42.
163. Maniadakis N, Gray A.The economiconomic burden of back pain in theUK. Pain.2000; 84:95-103.
164. BUPA. Health information, ABC of health, back pain. http://hcd2.bupa.co.uk/fact_sheets/mosby_factsheets/backpain.html (accessed8 Apr 2005).
165. Fritzell P, Hägg P, Wessburg P, Nordwall A.2001 Volvo awardwinner in clinical studies: lumbar fusion versus nonsurgicaltreatment for chronic low back pain. A multicenter randomizedcontrolled trial from the Swedish lumbar spine group. Spine.2001; 26:2521-34.
166. Moller H, Hedlund R.Surgery versus conservative management inadult isthmic spondylolisthesis-a prospective randomized study:part 1. Spine.2000; 25:1711-5.
167. Brox JI, Sorensen R, Friis A, Nygaard O, Indahl A, Keller A, et al.Randomized clinical trial of lumbar instrumented fusion andcognitive intervention and exercises in patients with chronic lowback pain and disc degeneration. Spine 2003; 28:1913-21.
168. Fairbank J, Frost H, Wilson-MacDonald J, Yu L, Barker K,Collins R, for the Spine Stabilisation Trial Group. The MRCspine stabilisation trial: a randomised controlled trial to comparesurgical stabilisation of the lumbar spine versus an intensiverehabilitation programme for patients with chronic low back pain.BMJ 2005;330: (in press, May 28 issue).
169. Fairbank JC, Couper J, Davies JB, O'Brien JP.The Oswestry lowback pain disability questionnaire. Physiotherapy.1980; 66:271-3.
170. Fairbank JC, Pynsent PB.The Oswestry disability index. Spine.2000; 25:2940-52.
171. EuroQol Group.EuroQol-a new facility for the measurement ofhealth-related quality of life. Health Policy.1990; 16:199-208.
172. Netten A, Curtis L. Unit costs of health and social care. Canterbury:Personal Social Services Research Unit, University of Kent, 2003.
173. MASS Group.Multicentre aneurysm screening study (MASS):cost-effectiveness analysis of screening for abdominal aorticaneurysms based on four year results from a randomizedcontrolled trial. BMJ.2002; 325:1135-41.
174. Dion P. The cost of anaesthetic vapours. Can J Anaesthesia 1992;39:633.
175. Chartered Institute of Public Finance and Accountancy. The healthservice financial database and comparative tool. Croydon: Instituteof Public Finance, 2000.
176. Mallender Hancock Associates (MHA). National average specialtytreatment and hotel costs. London: Department of Health, 4.
177. Information Services Division NHS Scotland. The cost book 2003.www.isdscotland.org/isd/info3.jsp?p_service=Content.show&pContentID=360&p_applic=CCC& (accessed 1 Jul 2004).
178. Department of Health. NHS reference costs 2003. Wetherby:DoH, 2004.
179. Bulman J. Patterns of pay: results of the 2003 new earningssurvey. In: Labour Market Trends. Newport, Wales: Office forNational Statistics, 2003:601-12.
180. Dolan P, Gudex C, Kind P, Williams A.The time trade-offmethod: results from a general population study. Health Econ.1996; 5:141-54.
181. Great Britain H.M. Treasury. Green book, appraisal and evaluationin central government. London: Stationery Office, 2003.
182. Van Buuren S, Boshuizen H, Knook D.Multiple imputation ofmissing blood pressure covariates in survival analysis. Stat Med.2000; 18:681-94.
183. Briggs AH, Wonderling DE, Mooney CZ.Pulling cost-effectivenessanalysis up by its bootstraps: a non-parametric approach to confi-dence interval estimation. Health Econ.1997; 6:327-40.
184. Van Hout BA, Al MJ, Gordon GS, Rutten FF.Costs, effects and theC/E ratios alongside a clinical trial. Health Econ.1994; 3:309-19.
185. Rawlins MD, Culyer AJ.National Institute for Clinical Excellenceand its value judgments. BMJ.2004; 329:224-7.
186. Fritzell P, Hagg O, Jonsson D, Nordwall A.Cost-effectivenessof lumbar fusion and nonsurgical treatment for chronic lowback pain in the Swedish lumbar spine study: a multicenter,randomized, controlled trial from the Swedish Lumbar SpineStudy Group. Spine.2004; 29:421-34.
187. Skouen JS, Gradsal AL, Haldorsen EM, Ursin H.Relativecost-effectiveness of extensive and light multidisciplinarytreatment programs versus treatment as usual for patients withchronic low back pain on long term sick leave: randomizedcontrolled study. Spine.2002; 27:901-9.
188. Kuntz KM, Snider RK, Weinstein JN, Pope MH, Katz JN.Cost-effectiveness of fusion with and without instrumentationfor patients with degenerative spondylolisthesis and spinalstenosis. Spine 2000; 25:1132-9.
189. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.)Hillsdale, NJ: Lawrence Erlbaum Associates, 1988; pp 75-108.
190. Zou KH, Tuncali K, Silverman SG.Correlation and simple linearregression. Radiology.2003; 227:617-628.
191. Altman DG. Interpretation of correlation. In: Practical statistics formedical research. London: Chapman & Hall, 1991; pp 296-299.
192. Bland JM, Altman DG.Measurement error and correlationcoefficients. BMJ.1996; 313:41-42.
193. Bland JM. Regression and correlation. In: An introduction to medicalstatistics. Oxford: Oxford University Press, 1996; pp 180-504.
194. Altman DG. Reference intervals. In: Practical statistics for medicalresearch. London: Chapman & Hall, 1996; pp 419-426.
195. Belousova EG, Haby MM, Xuan W, Peat JK.Factors that affectnormal lung function in white Australian adults. Chest.1997; 112:1539-1546.
196. Bland JM and Altman DG.Measurement error and correlationcoefficients. BMJ.1996; 313:41-42.
197. Kleinbaum DJ, Kupper LL, Muller KE, Nizam A. Applied regressionanalysis and other multivariable methods. Duxbury Press., 1998.
198. Nagy TR, Gower BA, Trowbridge CA, Dezenberg C, Shewchuk RM,Goran MI.Effects of gender, ethnicity, body composition, and fatdistribution on serum leptin concentrations in children. J Clin EndoMet.1997; 82:2148-2152.
199. Roemmich JN, Clark PA, Lusk M, Friel A, Weltman A, Epstein LH,Rogol AD. Pubertal alterations in growth and body composition.VI. Pubertal insulin resistance: relation to adiposity, body fatdistribution and hormone release. Int J Obes 2002; 26: 701-709
200. Soldan W, Henker J, Sprossig C.Sensitivity and specificity of quantitative determination of pancreatic elastase in feces ofchildren. J Pediatr Gastroenterol Nutr.1997; 24:53-5.
201. Von Seebach K, Henker J. Pancreatic Elastase in feces of pretermand term born infants up to 12 months without insuffisiancy ofexocrine pancreatic function [abstract]. 21st European Cystic FibrosisConference, Davos (Switzerland), June 1-6, 1997.
202. Campeotto F, Kapel N, Kalach N, et al.Evaluation de la fonctionpancréatique exocrine du nouveau-né à terme et du prématuré aucours de la première semaine de vie par le dosage de l'élastase 1fécale. Arch Pediatr.2001; 8:445-6.
203. Hamwi A, Veitl M, Maenner G, et al.Pancreatic elastase in stool:variations within one stool passage and individual changes from dayto day. Wien Klin Wochenschr.2000; 112:32-5.
204. Terbrack HG, Gurtler KH, Klor HU, et al. Human pancreatic elastase1 concentrations in faeces of healthy children and children withcystic fibrosis. Gut 1995;37:(SUPPL 2):A253.
205. Walkowiak J.Faecal elastase-1: clinical value in the assessment ofexocrine pancreatic function in children. Eur J Pediatr.2000; 159:869-70.
206. Burrin DG, Stoll B, Jiang R, et al. Minimal enteral nutrientrequirements for intestinal growth in neonatal piglets: how much isenough? Am J Clin Nutr 2000; 71:1603-10.
207. Thureen PJ. Early aggressive nutrition in the neonate. Pediatrics inReview 1999;20:e45-55.
208. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C.Randomised, double blind, placebo controlled crossover trial ofsustained release morphine for the management of refractorydyspnoea. BMJ 2003; 327:523-528.
209. Sibbald B, Roberts C.Understanding controlled trials: Crossovertrials. BMJ.1998; 316:1719-1720.
210. Altman DG, Dore CJ.Randomisation and baseline comparisons inclinical trials. Lancet.1990; 335:149-153.
211. Vickers AJ, Altman DG.Analysing controlled trials with baseline andfollow up measurements. BMJ.2001; 323:1123-1124.
212. Bland JM, Altman DG. Regression towards the mean. BMJ 1994;308:1499.
213. Roberts C, Torgerson DJ. Understanding controlled trials: Baselineimbalance in randomised controlled trials. BMJ 1999;319:185.
214. Fitzmaurice G. A conundrum in the analysis of change. Nutrition 2001;17:360-361.
215. Bland JM, Altman DG. Regression towards the mean. BMJ1994;308:1499.
216. Bland JM, Altman DG. Some examples of regression towards themean. BMJ 1994;309:780.
217. Senn S.Baseline comparisons in randomized clinical trials. Stat Med.1991; 10:1157-9.
218. Kleinhenz J, Streitberger K, Windeler J, Gussbacher A, Mavridis G,Martin E. Randomised clinical trial comparing the effects of acupunctureand a newly designed placebo needle in rotator cuff tendonitis.Pain 1999; 83:235-41.
219. Altman DG, Gardner MJ. Regression and correlation. In:Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statisticswith confidence. 2nd ed. London: BMJ Books, 2000:73-92.
220. Vickers AJ. The use of percentage change from baseline as an outcomein a controlled trial is statistically inefficient: a simulationstudy. BMC Med Res Methodol 2001;1:16.
221. Altman DG, Bland JM.How to randomise. BMJ.1999; 319:703-4.
222. Bland JM, Altman DG. The use of transformation when comparingtwo means. BMJ 1996;312:1153.
223. Katz J. Lumbar spinal fusion: surgical rates, costs, and complications.Spine 1995;20:78S-83S.
224. Department of Health (England). Hospital episode statistics,1998-2003. London: DoH, 1998-2003.
225. Cherkin D, Deyo R, Loeser J, Bush T, Waddell G.An internationalcomparison of back surgery rates. Spine.1994; 19:1201-6.
226. Deyo RA, Gray DT, Kreuter W, Mirza S, Martin, BI. United Statestrends in lumbar fusion surgery for degenerative conditions. Spine 2005 (in press).
227. Gibson J, Grant I, Waddell G.The Cochrane review of surgery forlumbar disc prolapse and degenerative lumbar spondylosis. Spine.1999; 24:1820-32.
228. Mayer T, Gatchel R, Kishino N.Objective assessment of spinefunction following industrial injury. A prospective studywith comparison group and one year follow up. Spine.1985; 10:482-93.
229. Lindstrom I, Ohlund C, Eek C. The effect of graded activity onpatients with sub acute low back pain: A randomised prospectiveclinical study with an operant conditioning behavioural approach.Phys Ther 1992; 72:279-93.
230. Guzman J, Esmail R, Karjalainen K, Malmivaara A, Irvin E,Bombardier C.Multidisciplinary rehabilitation for chronic lowback pain: systematic review. BMJ.2001; 322:1511-6.
231. NHS Standing Group. Health technology (SGHT) report. London:Department of Health, 1994.
232. Turner J, Ersek M, Herron L, Heselkorn J, Kent D, Ciol M,et al.Patient outcomes after lumbar spinal fusions. JAMA.1992; 268:907-11.
233. Weijer C, Shapiro S, Cranley Glass K.For and against: clinicalequipoise and not the uncertainty principle is the moral underpinningof the randomised controlled trial. BMJ.2000; 321:756-8.
234. Fairbank J, Pynsent P.The Oswestry Disability Index. Spine.2000; 25:2940-53.
235. Roland M, Fairbank J.The Roland-Morris disability questionnaireand the Oswestry disability questionnaire. Spine.2000; 25:3115-24.
236. Taylor S, Frost H, Taylor A, Barker K. Reliability and responsivenessof the shuttle walking test in patients with chronic low back pain.Physiother Res Int 2001; 6:170-8.
237. Frost H, Lamb S, Shackleton C. A functional restoration programmefor chronic low back pain: a prospective outcome study.Physiotherapy 2000; 86:285-93.
238. Pratt R, Fairbank J, Virr A.The reliability of the shuttle walkingtest, the Swiss spinal stenosis questionnaire, the Oxford spinalstenosis Score, and the Oswestry disability index in the assessmentof patients with lumbar spinal stenosis. Spine.2002; 27:84-91.
239. Main CJ, Wood PLR, Hollis S, Spanswick CC, Waddell G.The distressand risk assessment method: A simple patient classificationto identify distress and evaluate the risk of poor outcome. Spine.1992; 17:42-52.
240. Royston P.Multiple imputation of missing values. Stata J.2004; 4:227-41.
241. Möller H, Hedlund R.Surgery versus conservative treatment inadult isthmic spondylolisthesis. A prospective randomized studypart 1. Spine.2000; 25:1171-5.
242. Fritzell P, Hagg O, Wessburg P, Nordwall A, Group SLSS.Chronicback pain and fusion: a comparison of three surgical techniques:a prospective multicentre randomized study from the SwedishLumbar Spine Study Group. Spine.2002; 27:1131-41.
243. Brox J, Sørensen R, Friis A, Nygaard Ø, Indahl A, Keller A, et al.Randomized clinical trial of lumbar instrumented fusion and cognitiveintervention and exercises in patients with chronic low backpain and disc degeneration. Spine 2003; 28:1913-21.
244. Schonstein E, Kenny D, Keating J, Koes B, Herbert R. Physicalconditioning programs for workers with back and neck pain: aCochrane systematic review. Spine 2003;28(19):E391-5.
245. Liddle S, Baxter G, Gracey J. Exercise and chronic low back pain:what works? Pain 2004; 107:176-90.
246. European Commission Rersearch Directorate General. COST B13Management Committee. European guidelines for the managementof low back pain. www.backpaineurope.org, 2005 (accessed 17May 2005).
247. Hägg O, Fritzell P, Elkselius L, Nordwall A.Predictors of outcomein fusion surgery for chronic low back pain. A report from theSwedish lumbar spine study. Eur Spine J.2003; 12:22-33.
248. Taylor S, Taylor A, Foy M, Fogg A.Responsiveness of c ommon outcomemeasures for patients with low back pain. Spine.1999; 24:1805-12.
249. Pocock SJ, Clayton TC, Altman DG.Survival plots of timeto-event outcomes in clinical trials: good practice and pitfalls. Lancet.2002; 359:1686-1689.
250. Altman DG, Bland JM. Statistics notes: Time to event (survival) data.BMJ 1998; 317:468-469.
251. Bland JM, Altman DG. Statistics notes: Survival probabilities(the Kaplan-Meier method). BMJ 1998;317:1572.
252. Peat JK, Barton B. Survival analyses. In: Medical Statistics. A guideto data analysis and critical appraisal. Harayana, India: BMJ BooksBlackwell Publishing, 2005; pp 296-305.
253. Altman DG. Analysis of survival times. In: 5. Practical statistics formedical research. London: Chapman & Hall, 1996; pp 365-387.
254. Altman DG, Andersen, PK.Calculating the number needed to treatwhere the outcome is time to an event. BMJ.1999; 319:1492-1495.
255. Bull K, Spiegelhalter DJ. Survival analysis in observational studies.Stat Med 1997; 16:1041-1074.
256. Spruance SL, Reid JE, Grace M, Samore M.Hazard ratio in clinicaltrials. AAC.2004; 48:2787-2792.
257. Kaplan EL, Meier P.Nonparametric estimation from incompleteobservations. J Am Stat Assoc.1958; 53:457-81.
258. Collett D. Modelling survival data in medical research, section 2.1.London: Chapman and Hall, 1994.
259. Altman DG. Practical statistics for medical research, chapter 13.London: Chapman and Hall, 1991.
260. Altman DG, De Stavola BL, Love SB, Stepniewska KA.Review ofsurvival analyses published in cancer journals. Br J Cancer.1995; 72:511-18.
261. RITA-2 Trial Participants.Coronary angioplasty versus medicaltherapy for angina: the second Randomised Intervention Treatmentof Angina (RITA-2) trial. Lancet.1997; 350:461-68.
262. Pitt B, Poole-Wilson A, Segal R, et al.Effect of losartan comparedwith captopril on mortality in patients with symptomatic heartfailure: randomised trial-the Losartan Heart Failure SurvivalStudy ELITE II. Lancet.2000; 355:1582-87.
263. Hall A. Comparison of losartan and captopril in ELITE II. Lancet 2000; 356: 851.
264. Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatinin 3260 patients with unstable angina: results from the LIPID study.Lancet 2000; 356:1871-75.
265. Matthay KM, Villablanca JG, Seeger RC, et al. Treatment of highriskneuroblastoma with intensive chemotherapy, radiotherapy,autologous bone marrow transplantation, and 13-cis-retinoic acid.N Engl J Med 1999; 341:1165-73.
266. Altman DG, Anderson PK.Calculating the number 10 umber needed totreat for trials where the outcome is time to an event. BMJ.1999; 319:1492-95.
267. Lubsen J, Hoes A, Grobbee D.Implications of trial results: thepotentially misleading notions of number needed to treat andaverage duration of life gained. Lancet.2000; 356:1757-59.
268. Ruggenenti P, Perna A, Gherardi G, et al.Renoprotectiveproperties of ACE-inhibition in non-diabetic nephropathies withnon-nephrotic proteinuria. Lancet.2000; 354:359-64.
269. Scandinavian Simvastatin Survival Study Group.Randomisedtrial of cholesterol lowering in 4444 patients with coronary heartdisease: the Scandinavian Simvastatin Survival Study (4S). Lancet.1994; 344:1383-89.
270. Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics withconfidence, chapter 9. London: BMJ Publishing, 2000.
271. Boutitie F, Gueyffier F, Pocock SJ, Boissel J-P.Assessing treatmenttimeinteraction in clinical trials with time to event data: ameta-analysis of hypertension trials. Stat Med.1998; 17:2883-903.
272. Wilson EB.Probable inference, the law of succession, and statisticalinference. J Am Stat Assoc.1927; 22:209-12.
273. Newcombe R.Two sided confidence intervals for the singleproportion: a comparative evaluation of seven methods. Stat Med.1998; 17:857-72.
274. Mavroudis C, Jacobs JP. Congenital heart surgery nomenclatureand database project: Overview and minimum dataset. Ann ThoracSurg 2000;69:S2-17.
275. Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH,Iezzoni LI.Consensus-based method for risk adjustment forsurgery for congenital heart disease. J Thorac Cardiovasc Surg.2002; 123:110-18.
276. Gallivan S, Davis KB, Stark JF.Early identification of divergentperformance in congenital cardiac surgery. Eur J Cardiothorac Surg.2001; 20:1214-9.
277. Lacour-Gayet F, Maruszewski B, Mavroudis C, Jacobs JP,Elliott MJ.Presentation of the international nomenclature forcongenital heart surgery. The long way from nomenclature to collectionof validated data at the EACTS. Eur J Cardiothorac Surg.2000; 18:128-35.
278. Franklin RC, Anderson RH, Daniels O, Elliott M, Gewillig MH,Ghisla R, et al. Report of the coding committee of the Associationfor European Paediatric Cardiology. Cardiol Young 2000;10(SUPPL 1):1-26.
279. Nieminen HP, Jokinen EV, Sairanen HI.Late results of pediatriccardiac surgery in Finland: a population-based study with 96%follow-up. Circulation.2001; 104:570-5.
280. Stark J, Gallivan S, Lovegrove J, Hamilton JR, Monro JL,Pollock JC, et al.Mortality rates after surgery for congenitalheart defects in children and surgeons' performance. Lancet.2000; 355:1004-7.
281. Aylin P, Alves B, Best N, Cook A, Elliott P, Evans SWJ, et al.Comparison of UK paediatric cardiac surgical performance byanalysis of routinely collected data 1984-1996: was Bristol anoutlier? Lancet 2001; 358:181-7.
282. Kerr C. Assessment of screening tests. In Kerr CB, Taylor R,Heard GS, eds, Handbook of public health methods, McGraw-Hill,Sydney, Australia, 1998; pp 623-626.
283. Knottnerus JA, van Weel C, Muris JWM.Evidence base of clinicaldiagnosis: Evaluation of diagnostic procedures. BMJ.2002; 324:477-480.
284. Greenhalgh T.How to read a paper. Papers that report diagnostic orscreening tests. BMJ.1997; 315:540-543.
285. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ 1994;309:102.
286. Altman DG, Bland JM. Diagnostic tests 1: sensitivity and specificity.BMJ 1994;308:1552.
287. Jaeschke R, Guyatt GH, Sackett DL.Users' guides to the medicalliterature. III. How to use an article about a diagnostic test. B. Whatare the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA.1994; 271:703-707.
288. Loong T-W.Understanding sensitivity and specificity with the rightside of the brain. BMJ.2003; 327:716-719.
289. Sackett DL.On some clinically useful measures of the effects oftreatment. Evidence-Based Med.1996; 1:37-38.
290. Sackett DL, Haynes RB.Evidence base of clinical diagnosis: Thearchitecture of diagnostic research. BMJ.2002; 324:539-541.
291. http://en.wikipedia.org/wiki/mammography.
292. http://www.acpm.org/breast.htm.
293. Lidbrink E, Elfving J, Frisell J, Jonsson E.Neglected aspects offalse positive findings of mammograph in breast screening: analysisof false positive cases from the Stockholm trial. BMJ.1996; 312:273-276.
294. Kriege M, Brekelmans CT, Boetes C, et al.Efficacy of MRI andmammography for breast-cancer screening in women with a familialor genetic predisposition. N Engl J Med.2004; 351:427-437.
295. Attia J. Moving beyond sensitivity and specificity: using likelihoodratios to help interpret diagnostic tests. Aust Prescr 2003:26:111-113.
296. Jaescheke R, Guyatt G, Lijmer J. Diagnostic tests. In Guyatt G, RenneD, editors. Users' guide to the medical literature: A manual for evidencebased clinical practice. AMA Press, Chicago, 2002; pp 121-140.
297. Deeks JJ, Altman DG.Diagnostic tests 4: likelihood ratios. BMJ.2004; 329:168-169.
298. Bachmann LM, Puhan MA, Ter Riet G, Bossuyt PM.Samplesizes of studies on diagnostic accuracy: Literature survey. BMJ.2006; 332:1127-1129.
299. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP,Irwig LM, et al.Towards complete and accurate reporting of studiesof diagnostic accuracy: The STARD initiative. BMJ.2003; 326:41-44.
300. Cuckle HS, Wald NJ. Principles of screening. In: Antenatalnatal andneonatal screening. Oxford: Oxford University Press, 1984: 1-22.
301. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinicalepidemiology: a basic science for clinical medicine, 2nd edn.Boston: Little, Brown and Company, 1991.
302. Lang TA, Secic M. How to report statistics in medicine. Philadelphia:American College of Physicians, 1997.
303. Sawaya GF, Grimes DA.New technologies in cervical cytologyscreening: a word of caution. Obstet Gynecol.1999; 94:307-10.
304. US Preventive Services Task Force. Guide to clinical preventiveservices, 2nd edn. Baltimore: Williams and Wilkins, 1996.
305. Enkin M, Keirse MJNC, Neilson J, et al (eds). A guide to e ffective carein pregnancy and childbirth, 3rd edn. Oxford: Oxford UniversityPress, 2000.
306. Gabbe S, Hill L, Schmidt L, Schulkin J.Management of diabetes byobstetrician-gynecologists. Obstet Gynecol.1998; 91:643-47.
307. Feinstein AR.Clinical biostatistics XXXI: on the sensitivity,specificity, and discrimination of diagnostic tests. Clin PharmacolTher.1975; 17:104-16.
308. NIH Consensus Development Panel on Ovarian Cancer.Ovariancancer: screening, treatment, and follow-up. JAMA.1995; 273:491-97.
309. Wald N, Cuckle H.Reporting the assessment of screening anddiagnostic tests. Br J Obstet Gynaecol.1989; 96:389-96.
310. Myers ER, McCrory DC, Subramanian S, et al.Setting the target fora better cervical screening test: characteristics of a cost-effective testfor cervical neoplasia screening. Obstet Gynecol.2000; 96:645-52.
311. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL.Increased absenteeism from work after detection and labeling ofhypertensive patients. N Engl J Med 1978; 299:741-44.
312. Taylor DW, Haynes RB, Sackett DL, Gibson ES.Longterm follow-upof absenteeism among working men following the detection andtreatment of their hypertension. Clin Invest Med.1981; 4:173-77.
313. Feig DS, Chen E, Naylor CD.Self-perceived health status of womenthree to five years after the diagnosis of gestational diabetes: asurvey of cases and matched controls. Am J Obstet Gynecol.1998; 178:386-93.
314. Canadian Task Force on the Periodic Health Examination. TheCanadian guide to clinical preventive care. Ottowa: Minister ofSupply and Services Canada, 1994.
315. Yerushalmy J.Statistical problems in assessing methods of medicaldiagnosis, with special reference to X-ray techniques. Pub HealthRep.1947; 62:1432-49.
316. Youden WJ.Index for rating diagnostic tests. Cancer.1950; 3:32-35.
317. Griffith CS, Grimes DA.The validity of the postcoital test. Am JObstet Gynecol.1990; 162:615-20.
318. Begg CB.Biases in the assessment of diagnostic tests. Stat Med.1987; 6:411-23.
319. Hennekens CH, Buring JE. Epidemiology in medicine. Boston:Little, Brown and Company, 1987.
320. Riegelman RK, Hirsch RP. Studying a study and testing a test,2nd edn. Boston: Little, Brown and Company, 1989.
321. Gotzsche PC, Olsen O. Is screening for breast cancer withmammography justifiable? Lancet 2000; 355:129-34.
322. Olsen O, Gotzsche PC.Cochrane review on screening for breastcancer with mammography. Lancet.2001; 358:1340-42.
323. Horton R.Screening mammography: an overview revisited. Lancet.2001; 358:1284-85.
324. Hofmeyr GJ, Kulier R. External cephalic versionrsion for breechpresentation at term. Cochrane Database Syst Rev 2000; 2:CD000083.
325. Waterstone M, Bewley S, Wolfe C.Incidence and predictorsof severe obstetric morbidity: case-control study. BMJ.2001; 322:1089-93.
326. Watson WJ, Welter S, Day D.Antepartum identification of breechpresentation. J Reprod Med.2004; 49:294-6.
327. Thorp JM Jr, Jenkins T, Watson W.Utility of Leopoldmaneuvers in screening for malpresentation. Obstet Gynecol.1991; 78:394-6.
328. McFarlin BL, Engstrom JL, Sampson MB, Cattledge F.Concurrentvalidity of Leopold's maneuvers in determining fetal presentationand position. J Nurse Midwifery.1985; 30:280-4.
329. Lydon-Rochelle M, Albers L, Gorwoda J, Craig E, Qualls C.Accuracy of Leopold maneuvers in screening for malpresentation:a prospective study. Birth 1993; 20:132-5.
330. Roberts CL, Nassar N, Raynes-Greenow CH, Peat B. Update onthe management of term breech deliveries in NSW, Australia.Aust N Z J Obstet Gynaecol 2003;43:173.
331. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ 1994;309:102.
332. Scheer K, Nubar J.Variation of fetal presentation with gestationalage. Am J Obstet Gynecol.1976; 125:269-70.
333. Nassar N. Breech presentation: facilitating informed decisionmaking[dissertation]. Sydney, NSW: University of Sydney, 2005..